CTX-130
CRISPR Therapeutics AG
['lymsm', 'cobalt-lym', 'car-t', 'lymphoma']
on behalf of all cobalt-lym co-investigators, thankful to present ctx130 the first in human anti-cd70 car-t in t cell lymphoma- an area of huge unmet need. 70% orr and 30% cr with several ongoing responses. thankful for all patients who enrolled in the trial.#eha2022 #lymsm
Professor of Medicine, UT MD Anderson- T Lymphocytes - the good, the bad, and the re-engineered. and fueled by my opinions